Palak Shah

ORCID: 0000-0001-8175-168X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Mechanical Circulatory Support Devices
  • Cardiac Structural Anomalies and Repair
  • Transplantation: Methods and Outcomes
  • Cardiac Arrest and Resuscitation
  • Renal Transplantation Outcomes and Treatments
  • Heart Failure Treatment and Management
  • Cardiac pacing and defibrillation studies
  • Cardiovascular Function and Risk Factors
  • Organ Transplantation Techniques and Outcomes
  • Viral Infections and Immunology Research
  • Cardiomyopathy and Myosin Studies
  • Cardiac Valve Diseases and Treatments
  • Atherosclerosis and Cardiovascular Diseases
  • Cytomegalovirus and herpesvirus research
  • Cancer-related molecular mechanisms research
  • Acute Myocardial Infarction Research
  • Health Systems, Economic Evaluations, Quality of Life
  • Fuel Cells and Related Materials
  • Nutrition and Health in Aging
  • Galectins and Cancer Biology
  • Cancer Genomics and Diagnostics
  • Frailty in Older Adults
  • CRISPR and Genetic Engineering
  • Reproductive tract infections research
  • Cardiac Imaging and Diagnostics

Alaska Heart and Vascular Institute
2016-2025

National Heart Lung and Blood Institute
2025

Inova Fairfax Hospital
2015-2024

Johns Hopkins University
2012-2024

San Jose State University
2024

CVPath Institute
2023-2024

Bon Secours Heart & Vascular Institute
2021-2024

George Washington University
2011-2024

Inova Health System
2017-2024

Broad Institute
2023-2024

Cardiogenic shock (CS) is a multifactorial, hemodynamically complex syndrome associated with high mortality. Despite advances in reperfusion and mechanical circulatory support, management remains highly variable outcomes poor.This study investigated whether standardized team-based approach can improve CS risk score guide clinical decision making.A total of 204 consecutive patients were identified. etiology, patient demographic characteristics, right heart catheterization, support use,...

10.1016/j.jacc.2018.12.084 article EN cc-by-nc-nd Journal of the American College of Cardiology 2019-04-01

Each of the cardiomyopathies, classically categorized as hypertrophic cardiomyopathy, dilated cardiomyopathy (DCM), and arrhythmogenic right ventricular has a signature genetic theme. Hypertrophic are largely understood diseases sarcomere or desmosome proteins, respectively. In contrast, >250 genes spanning >10 gene ontologies have been implicated in DCM, representing complex diverse architecture. To clarify this, systematic curation evidence to establish relationship with DCM was conducted.

10.1161/circulationaha.120.053033 article EN cc-by Circulation 2021-05-05

A consensus conference on frailty in kidney, liver, heart, and lung transplantation sponsored by the American Society of Transplantation (AST) endorsed Nephrology (ASN), Transplant Surgeons (ASTS), Canadian (CST) took place February 11, 2018 Phoenix, Arizona. Input from transplant community through scheduled calls enabled wide discussion current concepts frailty, exploration best practices for risk assessment candidates management after transplant, development ideas future research....

10.1111/ajt.15198 article EN cc-by-nc-nd American Journal of Transplantation 2018-12-01
Douglas L. Mann Michael M. Givertz Justin M. Vader Randall C. Starling Palak Shah and 95 more Steven E. McNulty Kevin J. Anstrom Kenneth B. Margulies Michael S. Kiernan Claudius Mahr Divya Gupta Margaret M. Redfield Anuradha Lala Gregory D. Lewis Adam D. DeVore Patrice Desvigne‐Nickens Adrian F. Hernandez Eugene Braunwald Selma F. Mohammed Hellina Birru Etsubdink Aboye Phillip H. Lam Nicole Escobar Maria Cristina Domingues Fink Thomas P. Cappola Wendy Sheaffer Bonitta Reilly J W Ferree Ashwin Ravichandran Gina Ciezkowski Glenda Yamira Herrera Cevallos Hirsch Mehta Rosemarie Delucca Sanjay Doddamani Manreet Kanwar B. Thomas Laurie Machen J. Kim Athas Christina Brent C. Lampert Cindy Fontenelle Clement Eiswirth Julie Williams Darlene Rock Gregory F. Egnaczyk Enya Rentas-Sherman Deborah Barr Arvind Bhimaraj Adrianna Damato Christine Calayo John M. Herre JoAnn Lindenfeld Amanda Carroll Mary Gordon Mary Keebler Bandaa Setliff Sanjeev Gulati K Winkler Laura Curtin Carly Ohmart John Halvorson James O. Mudd S. Albert Camacho Maryse Palardy Neha Shah Kristina Picardi Arun Krishnamoorthy Adrienne Maximin Douglas Horstmanshof Beverly Seiler Zi J. Xu S. Mersola E. Kransdorf W.H. Wilson Tang T. Fonk Eiran Z. Gorodeski Guilherme H. Oliveira Terrence Semenec Nadine Norton Julie Nichols Peter Leo Mark E. Dunlap G. Michael Felker Lacey D. Taylor Mary Sheehan Sharon Levine Diane Cocca-Spofford Liana Brooks Thomas F. Cunningham Nancy Acker Susan Milbrandt Janet Gatzke Víctor G. Dávila‐Román Anne Dirks Karen Bult Elizabeth Weber Mary Lesko Deana Mikhalkova Kathleen Fitzgerald David J. Whellan

<h3>Importance</h3> The use of sacubitril/valsartan is not endorsed by practice guidelines for in patients with New York Heart Association class IV heart failure a reduced ejection fraction because limited clinical experience this population. <h3>Objective</h3> To compare treatment valsartan advanced and recent symptoms. <h3>Design, Setting, Participants</h3> A double-blind randomized trial was conducted; total 335 were included. began on March 2, 2017, stopped early 23, 2020, owing to...

10.1001/jamacardio.2021.4567 article EN JAMA Cardiology 2021-11-03

10.1016/j.healun.2022.12.004 article EN The Journal of Heart and Lung Transplantation 2023-05-25

Background: After heart transplantation, endomyocardial biopsy (EMBx) is used to monitor for acute rejection (AR). Unfortunately, EMBx invasive, and its conventional histological interpretation has limitations. This a validation study assess the performance of sensitive blood biomarker—percent donor-derived cell-free DNA (%ddcfDNA)—for detection AR in cardiac transplant recipients. Methods: multicenter, prospective cohort recruited subjects collected plasma samples contemporaneously with...

10.1161/circulationaha.120.049098 article EN Circulation 2021-01-13

The hypothesis of the Dilated Cardiomyopathy Precision Medicine Study is that most dilated cardiomyopathy has a genetic basis. study returns results to probands and, when indicated, relatives. While both American College Medical Genetics and Genomics/Association for Molecular Pathology ClinGen's MYH7-cardiomyopathy specifications provide relevant guidance variant interpretation, further gene- disease-specific considerations were required cardiomyopathy. To this end, we tailored ClinGen...

10.1161/circgen.119.002480 article EN Circulation Genomic and Precision Medicine 2020-04-01

Background: Little is known about clinical characteristics, hospital course, and longitudinal outcomes of patients with cardiogenic shock (CS) related to heart failure (HF-CS) compared acute myocardial infarction (AMI; CS AMI [AMI-CS]). Methods: We examined in-hospital 1-year 520 (219 AMI-CS, 301 HF-CS) consecutive (January 3, 2017–December 31, 2019) in a single-center registry. Results: Mean age was 61.5±13.5 years, 71% were male, 22% Black patients, 63% had chronic kidney disease. The...

10.1161/circheartfailure.121.009279 article EN Circulation Heart Failure 2022-06-01

<h3>Importance</h3> Idiopathic dilated cardiomyopathy (DCM) aggregates in families, and early detection at-risk family members can provide opportunity to initiate treatment prior late-phase disease. Most studies have included only White patients, yet Black patients with DCM higher risk of heart failure–related hospitalization death. <h3>Objective</h3> To estimate the prevalence familial among probands age-specific cumulative first-degree relatives across race ethnicity groups. <h3>Design,...

10.1001/jama.2021.24674 article EN JAMA 2022-02-01

Patients on left ventricular assist device (LVAD) support require chronic anticoagulation to reduce the risk of thromboembolic complications. Apixaban is a direct oral anticoagulant which has become first-line therapy; however, its safety in LVAD patients not been well-described. In with fully magnetically levitated LVAD, treatment apixaban will be feasible and comparable respect freedom from primary composite outcome death or major hemocompatibility-related adverse events (HRAE: stroke,...

10.1016/j.jchf.2024.04.013 article EN cc-by JACC Heart Failure 2024-05-07

BackgroundMolecular testing with gene expression profiling (GEP) and donor-derived cell-free DNA (dd-cfDNA) is increasingly used in the surveillance for acute cellular rejection (ACR) after heart transplant. However, performance of dual over each test individually has not been established. Further, impact non-invasive on clinical decision-making widely investigated.MethodsWe evaluated 2077 subjects from SHORE registry who were enrolled between 2018 2021 had verified biopsy data, categorized...

10.1016/j.healun.2024.05.003 article EN cc-by The Journal of Heart and Lung Transplantation 2024-05-15

BACKGROUND: Cell phenotype switching is increasingly being recognized in atherosclerosis. However, our understanding of the exact stimuli for such cellular transformations and their significance human atherosclerosis still evolving. Intraplaque hemorrhage thought to be a major contributor plaque progression part by stimulating influx CD163 + macrophages. Here, we explored hypothesis that macrophages cause through induction proapoptotic endothelial-to-mesenchymal transition (EndMT) within...

10.1161/circresaha.123.324082 article EN Circulation Research 2024-06-11

Continuous-flow left ventricular assist devices (CF-LVADs) have revolutionized the management of patients with advanced heart failure. Alternative implant strategies are increasingly used for device placement. We reviewed our experience from Mechanical Circulatory Support Research Network registry HeartWare centrifugal CF-LVAD (HVAD). From May 2004 to August 2015, 1,150 underwent primary implantation at institutions. Within this group, a total 283 (25%) were implanted HVAD. A minimally...

10.1097/mat.0000000000000714 article EN ASAIO Journal 2017-11-03
Coming Soon ...